{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:40:25Z","timestamp":1793889625289,"version":"4.8.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.euo.2021.09.006","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T21:44:31Z","timestamp":1635284671000},"page":"877-892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":564,"title":["Epidemiology and Prevention of Prostate Cancer"],"prefix":"10.1016","volume":"4","author":[{"given":"Giorgio","family":"Gandaglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Leni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddie","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r","family":"Stattin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrick","family":"Van Poppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"La Vecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2021.09.006_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2021.09.006_b0010","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/iju.13593","article-title":"Epidemiology of prostate cancer in Asian countries","volume":"25","author":"Kimura","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"10.1016\/j.euo.2021.09.006_b0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0025","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djw110","article-title":"Family history and probability of prostate cancer, differentiated by risk category: a nationwide population-based study","volume":"108","author":"Bratt","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2021.09.006_b0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.15430\/JCP.2019.24.2.91","article-title":"Occupational risk factors for prostate cancer: a meta-analysis","volume":"24","author":"Krstev","year":"2019","journal-title":"J Cancer Prev"},{"key":"10.1016\/j.euo.2021.09.006_b0040","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.euf.2018.04.001","article-title":"Impact of metabolic diseases, drugs, and dietary factors on prostate cancer risk, recurrence, and survival: a systematic review by the European Association of Urology Section of Oncological Urology","volume":"5","author":"Campi","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2021.09.006_b0045","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.euf.2018.02.007","volume":"5","author":"Brookman-May","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2021.09.006_b0050","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fonc.2019.00238","article-title":"Geographical variations in prostate cancer outcomes: a systematic review of international evidence","volume":"9","author":"Dasgupta","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.euo.2021.09.006_b0055","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/jnci\/djp278","article-title":"Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986\u20132005","volume":"101","author":"Welch","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2021.09.006_b0060","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2019.04.033","article-title":"Structured population-based prostate-specific antigen screening for prostate cancer: the European Association of Urology Position in 2019","volume":"76","author":"Gandaglia","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0065","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jnci\/djaa171","article-title":"Racial and ethnic variation in PSA testing and prostate cancer incidence following the 2012 USPSTF recommendation","volume":"113","author":"Kensler","year":"2021","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2021.09.006_b0070","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/cncr.32604","article-title":"Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF grade D recommendations against prostate-specific antigen screening in 2012","volume":"126","author":"Butler","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2021.09.006_b0075","doi-asserted-by":"crossref","unstructured":"Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. In press. https:\/\/doi.org\/10.1002\/ijc.33588.","DOI":"10.1002\/ijc.33588"},{"key":"10.1016\/j.euo.2021.09.006_b0080","unstructured":"United Nations Statistics Division. Standard country or area codes for statistical use (M49)."},{"key":"10.1016\/j.euo.2021.09.006_b0085","series-title":"Cancer incidence in five continents","author":"Doll","year":"1966"},{"key":"10.1016\/j.euo.2021.09.006_b0090","unstructured":"United Nations. United Nations development programme. Human development report 2020."},{"key":"10.1016\/j.euo.2021.09.006_b0095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00345-011-0801-1","article-title":"Familial risk and familial survival in prostate cancer","volume":"30","author":"Hemminki","year":"2012","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0100","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ijc.11466","article-title":"Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis","volume":"107","author":"Bruner","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euo.2021.09.006_b0105","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.juro.2014.09.018","article-title":"Incorporation of detailed family history from the Swedish family cancer database into the PCPT risk calculator","volume":"193","author":"Grill","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0110","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-5347(17)35617-3","article-title":"Hereditary prostate cancer: epidemiologic and clinical features","volume":"150","author":"Carter","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0115","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1200\/JCO.19.02808","article-title":"Risk of prostate cancer associated with familial and hereditary cancer syndromes","volume":"38","author":"Beebe-Dimmer","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2021.09.006_b0120","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2018.11.015","article-title":"Homeobox B13 G84E mutation and prostate cancer risk","volume":"75","author":"Nyberg","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0125","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41436-019-0596-9","article-title":"Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database","volume":"22","author":"Dominguez-Valentin","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.euo.2021.09.006_b0135","doi-asserted-by":"crossref","unstructured":"Plym A, Penney KL, Kalia S, et al. Evaluation of a multiethnic polygenic risk score model for prostate cancer. J Natl Cancer Inst. In press. https:\/\/doi.org\/10.1093\/jnci\/djab058.","DOI":"10.1093\/jnci\/djab058"},{"key":"10.1016\/j.euo.2021.09.006_b0140","doi-asserted-by":"crossref","first-page":"djv431","DOI":"10.1093\/jnci\/djv431","article-title":"Prostate cancer susceptibility in men of African ancestry at 8q24","volume":"108","author":"Han","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2021.09.006_b0145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eururo.2018.08.026","article-title":"Mutational profile of aggressive, localised prostate cancer from African Caribbean men versus European ancestry men","volume":"75","author":"Tonon","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0150","doi-asserted-by":"crossref","first-page":"djx084","DOI":"10.1093\/jnci\/djx084","article-title":"Two novel susceptibility loci for prostate cancer in men of African ancestry","volume":"109","author":"Conti","year":"2017","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2021.09.006_b0155","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41588-020-00748-0","article-title":"Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction","volume":"53","author":"Conti","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.euo.2021.09.006_b0160","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","article-title":"Association of black race with prostate cancer-specific and other-cause mortality","volume":"5","author":"Dess","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2021.09.006_b0165","first-page":"179","article-title":"Separate and unequal: residential segregation and black health disparities","volume":"19","author":"Landrine","year":"2009","journal-title":"Ethn Dis"},{"key":"10.1016\/j.euo.2021.09.006_b0170","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bju.15293","article-title":"The impact of racial residential segregation on prostate cancer diagnosis and treatment","volume":"127","author":"Poulson","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2021.09.006_b0175","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.eururo.2014.08.059","article-title":"A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies","volume":"66","author":"Islami","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0180","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.euf.2014.10.002","article-title":"Smoking and prostate cancer: a systematic review","volume":"1","author":"De Nunzio","year":"2015","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2021.09.006_b0185","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/annonc\/mdy073","article-title":"Physical activity in relation to risk of prostate cancer: a systematic review and meta-analysis","volume":"29","author":"Benke","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2021.09.006_b0190","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1001\/jama.291.13.1578","article-title":"Ejaculation frequency and subsequent risk of prostate cancer","volume":"291","author":"Leitzmann","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2021.09.006_b0195","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.eururo.2016.03.027","article-title":"Ejaculation frequency and risk of prostate cancer: updated results with an additional decade of follow-up","volume":"70","author":"Rider","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0200","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jsxm.2018.07.004","article-title":"Sexual activity and risk of prostate cancer: a dose-response meta-analysis","volume":"15","author":"Jian","year":"2018","journal-title":"J Sex Med"},{"key":"10.1016\/j.euo.2021.09.006_b0205","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bju.12843","article-title":"Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study","volume":"115","author":"Sourbeer","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2021.09.006_b0210","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/pcan.2017.1","article-title":"Meta-analysis of metabolic syndrome and prostate cancer","volume":"20","author":"Gacci","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2021.09.006_b0215","article-title":"Impact of metabolic syndrome on oncologic outcomes at radical prostatectomy","volume":"36","author":"Morlacco","year":"2018","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.euo.2021.09.006_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103177","article-title":"Chronic inflammation towards cancer incidence: a systematic review and meta-analysis of epidemiological studies","volume":"157","author":"Michels","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.euo.2021.09.006_b0225","doi-asserted-by":"crossref","first-page":"31358","DOI":"10.1038\/srep31358","article-title":"Hypertension and risk of prostate cancer: a systematic review and meta-analysis","volume":"6","author":"Liang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2021.09.006_b0230","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.clinthera.2020.06.021","article-title":"Association between the overall risk of prostate cancer and use of calcium channel blockers: a systematic review and meta-analysis","volume":"42","author":"Yang","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.euo.2021.09.006_b0235","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.2337\/dc20-0204","article-title":"Association of type 2 diabetes with cancer: A meta-analysis with bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people","volume":"43","author":"Ling","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.euo.2021.09.006_b0240","first-page":"735","article-title":"Why are diabetics at reduced risk for prostate cancer? A review of the epidemiologic evidence","volume":"30","author":"Pierce","year":"2012","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.euo.2021.09.006_b0245","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3810\/pgm.2009.05.2001","article-title":"Hypogonadotropic hypogonadism in men with type 2 diabetes","volume":"121","author":"Dandona","year":"2009","journal-title":"Postgrad Med"},{"key":"10.1016\/j.euo.2021.09.006_b0250","doi-asserted-by":"crossref","first-page":"930","DOI":"10.2337\/dc07-1962","article-title":"Serum prostate-specific antigen levels in men with type 2 diabetes","volume":"31","author":"Fukui","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.euo.2021.09.006_b0255","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/pcan.2011.28","article-title":"Diabetes and prostate cancer risk in the REDUCE trial","volume":"14","author":"Wu","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2021.09.006_b0260","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.eururo.2014.04.027","article-title":"Metformin use and prostate cancer risk","volume":"66","author":"Preston","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0265","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/21681805.2016.1271353","article-title":"Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer","volume":"51","author":"Haring","year":"2017","journal-title":"Scand J Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0270","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/CEJ.0000000000000514","article-title":"Effect of metformin on the risk of prostate cancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies","volume":"29","author":"Wang","year":"2020","journal-title":"Eur J Cancer Prev"},{"issue":"494","key":"10.1016\/j.euo.2021.09.006_b0275","first-page":"e1","article-title":"Waist circumference, waist-hip ratio, body mass index, and prostate cancer risk: results from the North-American case-control study Prostate Cancer & Environment Study","volume":"33","author":"Boehm","year":"2015","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.euo.2021.09.006_b0280","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/sj.bjc.6606066","article-title":"Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study","volume":"104","author":"Dimitropoulou","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2021.09.006_b0285","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.298.19.2275","article-title":"Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer","volume":"298","author":"Ba\u00f1ez","year":"2007","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.euo.2021.09.006_b0290","first-page":"431","article-title":"Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen","volume":"31","author":"Harrison","year":"2020","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.euo.2021.09.006_b0295","doi-asserted-by":"crossref","first-page":"djw225","DOI":"10.1093\/jnci\/djw225","article-title":"Prediagnostic body mass index trajectories in relation to prostate cancer incidence and mortality in the PLCO Cancer Screening Trial","volume":"109","author":"Kelly","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2021.09.006_b0300","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3892\/ol.2014.2841","article-title":"Impact of obesity upon prostate cancer-associated mortality: a meta-analysis of 17 cohort studies","volume":"9","author":"Zhang","year":"2015","journal-title":"Oncol Lett"},{"key":"10.1016\/j.euo.2021.09.006_b0305","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.12659\/MSM.893579","article-title":"Gonorrhea and prostate cancer incidence: an updated meta-analysis of 21 epidemiologic studies","volume":"21","author":"Lian","year":"2015","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.euo.2021.09.006_b0310","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/13685538.2018.1455178","article-title":"Human papillomavirus and risk of prostate cancer: a systematic review and meta-analysis","volume":"23","author":"Russo","year":"2020","journal-title":"Aging Male"},{"key":"10.1016\/j.euo.2021.09.006_b0315","doi-asserted-by":"crossref","first-page":"E1015","DOI":"10.1002\/ijc.27619","article-title":"Prospective study of ultraviolet radiation exposure and risk of cancer in the United States","volume":"131","author":"Lin","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euo.2021.09.006_b0320","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002708","article-title":"Association between Cd exposure and risk of prostate cancer: a PRISMA-compliant systematic review and meta-analysis","volume":"95","author":"Ju-Kun","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.euo.2021.09.006_b0325","doi-asserted-by":"crossref","DOI":"10.7812\/TPP\/19.086","article-title":"Prostate cancer and asbestos: a systematic review and meta-analysis","volume":"24","author":"Dutheil","year":"2020","journal-title":"Perm J"},{"key":"10.1016\/j.euo.2021.09.006_b0330","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3390\/ijerph17041345","article-title":"Shift work and prostate cancer: an updated systematic review and meta-analysis","volume":"17","author":"Rivera-Izquierdo","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.euo.2021.09.006_b0335","article-title":"Fat intake is not linked to prostate cancer: a systematic review and dose-response meta-analysis","volume":"10","author":"Xu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2021.09.006_b0340","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41391-018-0105-2","article-title":"Higher baseline dietary fat and fatty acid intake is associated with increased risk of incident prostate cancer in the SABOR study","volume":"22","author":"Liss","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2021.09.006_b0345","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3109\/09637486.2015.1056111","article-title":"Fried food and prostate cancer risk: systematic review and meta-analysis","volume":"66","author":"Lippi","year":"2015","journal-title":"Int J Food Sci Nutr"},{"key":"10.1016\/j.euo.2021.09.006_b0350","doi-asserted-by":"crossref","first-page":"11779","DOI":"10.1158\/0008-5472.CAN-05-2191","article-title":"A prospective study of meat and meat mutagens and prostate cancer risk","volume":"65","author":"Cross","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2021.09.006_b0355","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/M19-0699","article-title":"Reduction of red and processed meat intake and cancer mortality and incidence a systematic review and meta-analysis of cohort studies","volume":"171","author":"Han","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.euo.2021.09.006_b0360","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3390\/nu13020516","article-title":"Consumption of sweet beverages and cancer risk. A systematic review and meta-analysis of observational studies","volume":"13","author":"Llaha","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.euo.2021.09.006_b0365","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1186\/s12885-016-2891-z","article-title":"Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta\u2013analysis","volume":"16","author":"Zhao","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2021.09.006_b0370","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.3390\/nu12082188","article-title":"Alcohol consumption and the risk of prostate cancer: a dose-response meta-analysis","volume":"12","author":"Hong","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.euo.2021.09.006_b0375","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2147\/CLEP.S163668","article-title":"The impact of moderate wine consumption on the risk of developing prostate cancer","volume":"10","author":"Vartolomei","year":"2018","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.euo.2021.09.006_b0380","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0278-6915(02)00029-7","article-title":"Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity","volume":"40","author":"Cavin","year":"2002","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.euo.2021.09.006_b0385","article-title":"Coffee consumption and risk of prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Chen","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.euo.2021.09.006_b0390","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.1093\/advances\/nmz014","article-title":"Milk and dairy product consumption and prostate cancer risk and mortality: an overview of systematic reviews and meta-analyses","volume":"10","author":"L\u00f3pez-Plaza","year":"2019","journal-title":"Adv Nutr"},{"key":"10.1016\/j.euo.2021.09.006_b0395","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/pcan.2017.25","article-title":"Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: a systematic review and meta-analysis","volume":"20","author":"Rowles","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2021.09.006_b0400","article-title":"Effect of carotene and lycopene on the risk of prostate cancer: a systematic review and dose-response meta-analysis of observational studies","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2021.09.006_b0405","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/andr.12196","article-title":"Is phytoestrogen intake associated with decreased risk of prostate cancer? A systematic review of epidemiological studies based on 17,546 cases","volume":"4","author":"Zhang","year":"2016","journal-title":"Andrology"},{"key":"10.1016\/j.euo.2021.09.006_b0410","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/nu10010040","article-title":"Soy consumption and the risk of prostate cancer: an updated systematic review and meta-analysis","volume":"10","author":"Applegate","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.euo.2021.09.006_b0415","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ijc.31095","article-title":"Dietary intake of isoflavones and coumestrol and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial","volume":"142","author":"Reger","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euo.2021.09.006_b0420","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016341","article-title":"Mediterranean dietary pattern and the risk of prostate cancer","volume":"98","author":"Cheng","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.euo.2021.09.006_b0425","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00394-020-02346-6","article-title":"An updated systematic review and meta-analysis on adherence to Mediterranean diet and risk of cancer","volume":"60","author":"Morze","year":"2021","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.euo.2021.09.006_b0430","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ijc.11375","article-title":"Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries","volume":"108","author":"Tuohimaa","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euo.2021.09.006_b0435","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/ijc.27327","article-title":"Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade","volume":"131","author":"Gilbert","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euo.2021.09.006_b0440","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1055-9965.EPI-14-0115","article-title":"Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial","volume":"23","author":"Kristal","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.euo.2021.09.006_b0445","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1809944","article-title":"Vitamin D supplements and prevention of cancer and cardiovascular disease","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2021.09.006_b0450","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1046\/j.1464-410X.2003.04167.x","article-title":"Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial","volume":"91","author":"Duffield-Lillico","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2021.09.006_b0455","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199404143301501","article-title":"The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers","volume":"330","author":"Kuban","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2021.09.006_b0460","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/jnci\/90.6.440","article-title":"Prostate cancer and supplementation with \u03b1-tocopherol and \u03b2-carotene: incidence and mortality in a controlled trial","volume":"90","author":"Heinonen","year":"1998","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2021.09.006_b0465","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin E and the risk of prostate cancer","volume":"306","author":"Klein","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2021.09.006_b0470","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2021.09.006_b0475","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1215932","article-title":"Long-term survival of participants in the Prostate Cancer Prevention Trial","volume":"369","author":"Thompson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2021.09.006_b0480","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2021.09.006_b0485","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/bju.14534","article-title":"Impact of 5\u03b1-reductase inhibitor and \u03b1-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality","volume":"123","author":"Van Rompay","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2021.09.006_b0490","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.juro.2014.06.071","article-title":"Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries","volume":"193","author":"Haider","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0495","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.juro.2015.05.099","article-title":"Long-term exposure to testosterone therapy and the risk of high grade prostate cancer","volume":"194","author":"Baillargeon","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0500","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bju.13417","article-title":"Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis","volume":"118","author":"Boyle","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2021.09.006_b0505","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.eururo.2015.12.005","article-title":"Testosterone therapy in men with prostate cancer","volume":"69","author":"Kaplan","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0510","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European Randomized study of Screening for Prostate Cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0515","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.annonc.2020.02.009","article-title":"European cancer mortality predictions for the year 2020 with a focus on prostate cancer","volume":"31","author":"Carioli","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2021.09.006_b0520","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1002\/cncr.32933","article-title":"Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer","volume":"126","author":"Patel","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2021.09.006_b0525","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pros.23923","article-title":"Disparities in prostate cancer incidence and mortality rates: solvable or not?","volume":"80","author":"Badal","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2021.09.006_b0530","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","article-title":"Epidemiology and genomics of prostate cancer in Asian men","volume":"18","author":"Zhu","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0535","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2021.09.006_b0540","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1158\/1055-9965.EPI-16-0434","article-title":"Screening men at increased risk for prostate cancer diagnosis: model estimates of benefits and harms","volume":"26","author":"Gulati","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.euo.2021.09.006_b0545","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/1055-9965.EPI-20-1005","article-title":"Rising prostate cancer incidence in Sub-Saharan Africa: a trend analysis of data from the African Cancer Registry Network","volume":"30","author":"Seraphin","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931121001814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931121001814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:47:45Z","timestamp":1762876065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931121001814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":109,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2588931121001814"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2021.09.006","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology and Prevention of Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2021.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}